Amanote Research
Register
Sign In
Venetoclax–Obinutuzumab Elicits High Response Rates in CLL
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2019-039
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
March 22, 2019
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)